Eltrombopag is a small-molecule, nonpeptide thrombopoietin receptor agonist with megakaryopoiesis-stimulating activity. Eltrombopag binds to and stimulates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of cells in the megakaryocytic lineage and an increase in platelet production. Eltrombopag was approved by FDA in November 20, 2008.

June 21, 2017

prudect name : Eltrombopag is a small-molecule, nonpeptide thrombopoietin receptor agonist with megakaryopoiesis-stimulating activity. Eltrombopag binds to and stimulates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of cells in the megakaryocytic lineage and an increase in platelet production. Eltrombopag was approved by FDA in November 20, 2008.
Eltrombopag olamine

Synonyms: CAS NO: 496775-62-3Molecular Formula: C₂₅H₂₂N₄O₄.₂(C₂H₇NO)Molecular Weight: 564.64Purity: 98% minSolubility: In DMSOStorage: -20°C

ACP196 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18513894